Skip to main content

HEAL-LAA Clinical Trial

Completed · Not applicable · NCT05809596

Conditions: Atrial Fibrillation, Bleeding, Stroke

At a glance

Research payments reported, 2025
$656,759
U.S. investigators named
43
Sites paid
41
Planned or actual enrollment
949

About the trial

Sponsor
Boston Scientific Corporation
Tested
WATCHMAN FLX Pro LAAC Device (device)
Dates
Started 2023-10-03; completion 2025-09-18
Results posted
Yes

The primary objective of this study is to collect real-world data on WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device in patients with non-valvular atrial fibrillation.

From ClinicalTrials.gov, last updated 2025-11-04. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $656,759 in research payments for this study in 2025 (357 payments).

Products named: Clinical Trial Product

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.